Expert Finance For Innovators At The Edge of Science

Science Moves Fast, Clinical Trials Don’t.
We Understand the Journey.

Standard accounting doesn’t work when your product takes years and millions to reach the market.

We know that in the life sciences sector, traditional financial modelling goes out the window. You need a partner who understands the mechanics of pre-revenue growth and the regulatory hurdles you face.

Funding the Long Haul: We help you map and manage the extended cash runways required to get through preclinical phases and Phase I/II trials, ensuring you don’t hit a financial wall before your science can prove itself.

Maximizing Non-Dilutive Capital: BioTech relies heavily on specialised funding. We are experts at navigating the intricate reporting requirements of Innovate UK, Horizon Europe, and other major grant bodies so you stay compliant and funded.

Valuing the Intangible: Before you have revenue, your value lies in your IP and data. We help you accurately track, capitalise, and present your research and development costs to maximise valuation during early funding rounds.

How We Add Value Beyond the Balance Sheet

Milestone-Driven Fractional CFO: Consider us your commercial co-founders. We build complex, scenario-based financial models tied directly to your scientific milestones, ensuring your board packs clearly translate clinical progress into financial value.

Specialist R&D Tax & Grant Audits: Your biggest financial lever is your research spend. We ensure you are claiming every eligible penny of R&D tax relief while providing the specialized grant audits required by major funding institutions.

Investor-Ready Audit & Tax: BioTech cap tables can get complicated quickly with multiple tranches, EIS/SEIS requirements, and institutional investors. We provide heavyweight audit and tax structuring that stands up to the strictest due diligence.

Licensing & M&A Readiness: Whether you are structuring a lucrative out-licensing agreement with a major pharma player or preparing the data room for a full acquisition, we help benchmark your valuation and structure the deal to protect founder equity.

Data-Driven Insights for Scientific Founders

We don’t just observe the life sciences sector; we actively track its financial pulse. Our deep integration within the deep-tech and biotech venture space means we know exactly how investors are currently pricing early-stage science.

Here is some of our latest research into the BioTech Market.

More Insights →

Startup Agility Meets Top 100 Muscle

As RouseFinerva, we bring you the best of both worlds. You get the agile, milestone-focused advisory and fractional CFO expertise of Finerva, backed entirely by the century-long, Top 100 audit and tax infrastructure of Rouse Partners. We are built to support you from your first seed round in the lab all the way to a global pharma buyout, without you ever needing to change firms.

Ready to scale your BioTech business with confidence?

Let’s talk about your clinical milestones, your runway, and your next funding round.